

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibilities for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CONCORD HEALTHCARE GROUP CO., LTD.**

**美中嘉和醫學技術發展集團股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2453)**

### **VOLUNTARY ANNOUNCEMENT**

## **APPROVAL REGARDING THE APPLICATION FOR THE REGISTRATION CERTIFICATE FOR MEDICAL DEVICE FOR THE PROTON THERAPY EQUIPMENT**

This announcement is made by the board of directors (the “**Board**”) of Concord Healthcare Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the prospectus of the Company dated December 29, 2023 (the “**Prospectus**”), annual results announcement for the year ended December 31, 2023 dated March 27, 2024, the annual report 2023 dated April 19, 2024, interim results announcement for the six months ended June 30, 2024 dated August 29, 2024 and the voluntary announcement dated September 14, 2024 in relation to the business update on photon therapy services (the “**Announcements**”). As disclosed in the Prospectus and the Announcements, Guangzhou Concord Cancer Center Co., Ltd. (廣州泰和腫瘤醫院有限公司), a company with limited liability incorporated in the People's Republic of China (the “**PRC**”) on June 29, 2011, which is owned as to 80% by the Company and operates under the trade name of Guangzhou Concord Cancer Hospital (廣州泰和腫瘤醫院) has procured one customized set of proton therapy equipment and commenced the clinical trial for the proton therapy equipment. The Company has submitted the application for the License for the Deployment of Large-scale Medical Equipment (the “**License**”) with the National Health Commission of the PRC (中華人民共和國國家衛生健康委員會) (the “**NHC**”) for the proton therapy equipment on April 29, 2024, and on September 13, 2024, the NHC has granted approval to the Company's application for the License.

The Board is pleased to announce that, on December 6, 2024, the National Medical Products Administration of the People's Republic of China has granted approval to the application for the Registration Certificate for Medical Device for the proton therapy equipment by the Company's equipment supplier.

The operation of proton therapy services would start as soon as possible after completing some preparations. The Company will provide further updates regarding the material progress of its planned proton therapy services as and when appropriate.

By Order of the Board  
**Concord Healthcare Group Co., Ltd.**  
美中嘉和醫學技術發展集團股份有限公司  
**YANG Jianyu**  
*Chairman of the Board and Executive Director*

Beijing, the PRC, December 9, 2024

*As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. CHEN Hongzhang and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.*